RIBOLIFE (06938.HK): EU filing for Phase I trial of SR122
- SR122 is a GalNAc-conjugated siRNA hitting ApoC3 and PCSK9, curbing triglyceride-rich lipoproteins and LDL-C for a synergistic lipid-lowering effect.
- RBD5044 is in Phase II in Europe and China.
NewTimeSpace News: On 10 November 2026, Suzhou Ribo Life Science Co., Ltd. (stock code: 06938) announced the submission of a Phase I clinical trial application (CTA) in the European Union for SR122, a self-developed dual-target siRNA drug. SR122 is a GalNAc-conjugated siRNA targeting ApoC3 and PCSK9, two clinically validated targets with complementary roles in lipid metabolism, for dyslipidaemia including severe hypertriglyceridaemia and mixed dyslipidaemia.
The Phase I trial is a randomised, placebo-controlled study in healthy volunteers assessing safety, tolerability, pharmacokinetics and pharmacodynamics, marking the first clinical evaluation of the dual-target drug in humans. The company said the filing further completes its lipid portfolio strategy, while Phase II studies of its core candidate RBD5044 continue in Europe and China.
- RIBOLIFE-B (06938.HK): Issues 14,087,085 Consideration Shares to Buy Remaining 49.71% of Ribocure
- RIBOLIFE-B (06938.HK): files EU Phase I trial for obesity drug RBD3133
- RIBOLIFE-B (06938.HK): Included in Hang Seng Composite Index constituents and Stock Connect list effective 7 September
- RIBOLIFE-B (06938.HK): Positive Phase IIa Results for Core Asset Vortosiran in CAD; Maximum FXI Activity Reduction Reaches 92%
